KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin: 2010-2024

Historic EBT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to 14.79%.

  • Supernus Pharmaceuticals' EBT Margin fell 5575.00% to -30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.04%, marking a year-over-year decrease of 1416.00%. This contributed to the annual value of 14.79% for FY2024, which is 1433.00% up from last year.
  • As of FY2024, Supernus Pharmaceuticals' EBT Margin stood at 14.79%, which was up 3,144.52% from 0.46% recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' EBT Margin peaked at 32.41% during FY2020, and registered a low of 0.46% during FY2023.
  • Its 3-year average for EBT Margin is 8.12%, with a median of 9.10% in 2022.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by 1,979bps in 2021, then soared by 1,433bps in 2024.
  • Supernus Pharmaceuticals' EBT Margin (Yearly) stood at 32.41% in 2020, then slumped by 1,979bps to 12.62% in 2021, then tumbled by 352bps to 9.10% in 2022, then plummeted by 865bps to 0.46% in 2023, then spiked by 1,433bps to 14.79% in 2024.